Research Publications

Dey, S., Udari, L. M., RiveraHernandez, P., Kwon, J. J., Willis, B., Easler, J. J., Fogel, E. L., Pandol, S., & Kota, J. (2021). Loss of miR-29a/b1 promotes inflammation and fibrosis in acute pancreatitis. JCI insight, 149539. Advance online publication. https://doi.org/10.1172/jci.insight.149539

Dey, S., Kwon, J. J., Liu, S., Hodge, G. A., Taleb, S., Zimmers, T. A., Wan, J., & Kota, J. (2020). miR-29a Is Repressed by MYC in Pancreatic Cancer and Its Restoration Drives Tumor-Suppressive Effects via Downregulation of LOXL2. Molecular cancer research: MCR, 18(2), 311–323. https://doi.org/10.1158/1541-7786.MCR-19-0594

Dey, S., Liu, S., Factora, T. D., Taleb, S., Riverahernandez, P., Udari, L., Zhong, X., Wan, J., & Kota, J. (2020). Global targetome analysis reveals critical role of miR-29a in pancreatic stellate cell mediated regulation of PDAC tumor microenvironment. BMC cancer, 20(1), 651. https://doi.org/10.1186/s12885-020-07135-2

Sahu, S. S., Dey, S., Nabinger, S. C., Jiang, G., Bates, A., Tanaka, H., Liu, Y., & Kota, J. (2019). The Role and Therapeutic Potential of miRNAs in Colorectal Liver Metastasis. Scientific reports, 9(1), 15803. https://doi.org/10.1038/s41598-019-52225-2

Kwon, J. J., Factora, T. D., Dey, S., & Kota, J. (2018). A Systematic Review of miR-29 in Cancer. Molecular therapy oncolytics, 12, 173–194. https://doi.org/10.1016/j.omto.2018.12.011

Jones, K. R., Nabinger, S. C., Lee, S., Sahu, S. S., Althouse, S., Saxena, R., Johnson, M. S., Chalasani, N., Gawrieh, S., & Kota, J. (2018). Lower expression of tumor microRNA-26a is associated with higher recurrence in patients with hepatocellular carcinoma undergoing surgical treatment. Journal of surgical oncology, 118(3), 431–439. https://doi.org/10.1002/jso.25156

Quirin, K. A., Kwon, J. J., Alioufi, A., Factora, T., Temm, C. J., Jacobsen, M., Sandusky, G. E., Shontz, K., Chicoine, L. G., Clark, K. R., Mendell, J. T., Korc, M., & Kota, J. (2017). Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice. Molecular therapy. Methods & clinical development, 8, 8–20. https://doi.org/10.1016/j.omtm.2017.09.006

Kota, J., Hancock, J., Kwon, J., & Korc, M. (2017). Pancreatic cancer: Stroma and its current and emerging targeted therapies. Cancer letters, 391, 38–49. https://doi.org/10.1016/j.canlet.2016.12.035

Adelaiye-Ogala, R., Budka, J., Damayanti, N. P., Arrington, J., Ferris, M., Hsu, C. C., Chintala, S., Orillion, A., Miles, K. M., Shen, L., Elbanna, M., Ciamporcero, E., Arisa, S., Pettazzoni, P., Draetta, G. F., Seshadri, M., Hancock, B., Radovich, M., Kota, J., Buck, M., … Pili, R. (2017). EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. Cancer research, 77(23), 6651–6666. https://doi.org/10.1158/0008-5472.CAN-17-0899

Surendran, S., Jideonwo, V. N., Merchun, C., Ahn, M., Murray, J., Ryan, J., Dunn, K. W., Kota, J., & Morral, N. (2016). Gene targets of mouse miR-709: regulation of distinct pools. Scientific reports, 6, 18958. https://doi.org/10.1038/srep18958

Kwon, J. J., Willy, J. A., Quirin, K. A., Wek, R. C., Korc, M., Yin, X. M., & Kota, J. (2016). Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential. Oncotarget, 7(44), 71635–71650. https://doi.org/10.18632/oncotarget.11928

Kwon, J. J., Nabinger, S. C., Vega, Z., Sahu, S. S., Alluri, R. K., Abdul-Sater, Z., Yu, Z., Gore, J., Nalepa, G., Saxena, R., Korc, M., & Kota, J. (2015). Pathophysiological role of microRNA-29 in pancreatic cancer stroma. Scientific reports, 5, 11450. https://doi.org/10.1038/srep11450

Rosales, X. Q., Malik, V., Sneh, A., Chen, L., Lewis, S., Kota, J., Gastier-Foster, J. M., Astbury, C., Pyatt, R., Reshmi, S., Rodino-Klapac, L. R., Clark, K. R., Mendell, J. R., & Sahenk, Z. (2013). Impaired regeneration in LGMD2A supported by increased PAX7-positive satellite cell content and muscle-specific microrna dysregulation. Muscle & nerve, 47(5), 731–739. https://doi.org/10.1002/mus.23669

Hsu, S. H., Wang, B., Kota, J., Yu, J., Costinean, S., Kutay, H., Yu, L., Bai, S., La Perle, K., Chivukula, R. R., Mao, H., Wei, M., Clark, K. R., Mendell, J. R., Caligiuri, M. A., Jacob, S. T., Mendell, J. T., & Ghoshal, K. (2012). Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. The journal of clinical investigation, 122(8), 2871–2883. https://doi.org/10.1172/JCI63539

Kota, J., Handy, C. R., Haidet, A. M., Montgomery, C. L., Eagle, A., Rodino-Klapac, L. R., Tucker, D., Shilling, C. J., Therlfall, W. R., Walker, C. M., Weisbrode, S. E., Janssen, P. M., Clark, K. R., Sahenk, Z., Mendell, J. R., & Kaspar, B. K. (2009). Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Science translational medicine, 1(6), 6ra15. https://doi.org/10.1126/scitranslmed.3000112

Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H. W., Chang, T. C., Vivekanandan, P., Torbenson, M., Clark, K. R., Mendell, J. R., & Mendell, J. T. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 137(6), 1005–1017. https://doi.org/10.1016/j.cell.2009.04.021

Rodino-Klapac, L. R., Haidet, A. M., Kota, J., Handy, C., Kaspar, B. K., & Mendell, J. R. (2009). Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle & nerve, 39(3), 283–296. https://doi.org/10.1002/mus.21244